PPTA welcomes the EC's proposal for the Regulation on the EU general pharmaceutical legislation (GPL) and its aim to harmonise regulatory provisions for manufacturers of medicines in the EU while ensuring better availability of medicines for EU patients. Overall, GPLs focus on strengthening the EU pharmaceutical supply chains is encouraging.
PPT
Plasma Protein Therapeutics Association
Industry association · Belgium · EU Transparency Register 687559214721-11
7
positions filed
in the 665 files tracked
4
legislative files
of 665 tracked
4
with a full position paper
attached to a submission
Counts here are a floor, never a total: they cover the 665 consultation files tracked so far (57,774 submissions, mostly 2021–26), so an organization's real filing history is larger, not smaller.
Who they are
Among the 1518 trade and business associations on this site, they rank #683 by legislative files engaged, a count of participation, not a measure of influence.
2.7
declared lobbying FTE
self-declared
€100K+
declared costs / yr (floor)
4
EP accreditations
as declared to the register
2014
in the register since
Declares membership of
- EU Health Coalition, Brussels
- https://www.euhealthcoalition.eu/partners/
Self-declared to the EU Transparency Register (snapshot 14 Oct 2026).
- Register category
- Trade and business associations
- Registered as
- Plasma Protein Therapeutics Association Europe, international Association without lucrative purpose (PPTA Europe aisbl)
- Head office
- Brussels, Belgium
Self-declared to the EU Transparency Register (snapshot 14 Oct 2026); cost bands are floors, not audited totals. Reused under Commission Decision 2011/833/EU.
Track Plasma in PolicySpeak: request access →
Work at Plasma Protein Therapeutics Association? so we know who speaks for it.
Their record over time
Plasma Protein Therapeutics Association filed 7 positions between 14 Dec 2020 and 9 Jul 2026, across 4 of the 665 legislative files tracked here, attaching a full position paper 4 times.
2020 · 1 filed2021 · 2 filed2022 · 1 filed2023 · 2 filed2026 · 1 filed
What they argued
PPTA welcomes the Commission's proposal for revision of the EU general pharmaceutical legislation and supports the overall objective to harmonise the rules governing pharmaceuticals in order to ensure better availability of medicines for EU patients. We welcome a more comprehensive definition of SoHO-derived medicinal product (Article 4 point 31).
The Plasma Protein Therapeutics Association (PPTA) promotes the availability of, and access to, safe and effective plasma-derived medicinal products (PDMPs) which treat a variety of rare, chronic, and potentially life-threatening conditions. 300,000 European patients rely on these essential medicines, without which they might not survive or would have a substantially diminished quality of life.
Plasma Protein Therapeutics Association (PPTA) is pleased to share feedback for the Biotech Act in the attached document. The plasma-derived medicinal products industry represents a significant and established component of Europes biotechnology ecosystem, with a substantial manufacturing footprint and contribution to employment and economic activity.
PPTA feedback on EU Commission proposal for a EU Regulation on standards of quality and safety for substances of human origin (SoHO) The EU Commission proposal for a SoHO Regulation is an opportunity to help ensure broad and reliable patient access to life-saving plasma-derived medicinal products (PDMPs) and the health and the safety of plasma donors.
The Plasma Protein Therapeutics Association (PPTA) is steadfast in its mission to promote the availability of, and access to, safe and effective plasma-derived medicinal products (PDMPs). 300,000 European patients rely on essential PDMPs to treat a variety of rare, chronic, and potentially life-threatening conditions.
The Plasma Protein Therapeutics Association (PPTA) promotes the availability of, and access to, safe and effective plasma-derived medicinal products (PDMPs) which treat a variety of rare, chronic, and potentially life-threatening conditions. 300,000 European patients rely on these essential medicines, without which they might not survive or would have a substantially diminished quality of life.
Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.
Put Plasma Protein Therapeutics Association next to another organization. Same files, same register facts, side by side. Compare →
Turns up on the same files
Organizations that also filed on at least two of the same consultations. A shared interest in the same dossiers, not evidence of coordination, and we do not suggest any.
Showing 5 of 106.
Is this your organization?
Everything on this page comes from Plasma Protein Therapeutics Association’s own submissions to the European Commission. We have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.
Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.